Burkitt lymphoma is an aggressive cancer of the immune system’s B cells, and it holds the distinction of being the fastest-growing tumor known in humans, with a doubling time of roughly 66 hours. Despite that alarming speed, it responds well to intensive chemotherapy, particularly in children, who have five-year survival rates above 90%.
How Burkitt Lymphoma Develops
Every case of Burkitt lymphoma traces back to a specific genetic accident. A piece of chromosome 8, carrying a gene called MYC, breaks off and attaches to chromosome 14, landing next to genetic switches that normally control antibody production. Those switches are always “on” in B cells, so MYC gets locked into overdrive. MYC is a master growth regulator. When it’s permanently activated, B cells divide uncontrollably, producing a tumor that can visibly enlarge in a matter of days.
This chromosomal swap is considered the hallmark of the disease and is present in virtually every case. The resulting cells look remarkably uniform under a microscope: medium-sized, round, and dividing at a rate approaching 100% of the tumor at any given time. That near-total proliferation rate is one of the key features pathologists use to confirm the diagnosis.
Three Clinical Subtypes
The World Health Organization recognizes three distinct forms, each tied to geography, infection patterns, and the age of the people it affects.
Endemic Burkitt Lymphoma
This form is concentrated in equatorial Africa and Papua New Guinea, regions where both the Epstein-Barr virus (EBV) and malaria are widespread. Nearly all endemic cases test positive for EBV, and research shows a direct correlation between higher malaria antibody levels and the development of this lymphoma. The prevailing theory is that chronic malaria weakens immune surveillance over EBV-infected B cells, giving cells with the MYC translocation a chance to survive and multiply.
The average age at diagnosis is just 6 years, with an incidence of roughly 3 to 6 cases per 100,000 children per year in affected regions. The classic presentation is a rapidly growing mass in the jaw or around the eye socket. Younger children are especially prone to jaw involvement.
Sporadic Burkitt Lymphoma
This is the form seen in the United States and Western Europe. Only a small fraction of sporadic cases are linked to EBV. The median age at diagnosis is 30 in adults, though it also appears in children between ages 3 and 12. Annual incidence runs about 4 per million in children under 16 and 2.5 per million in adults.
Rather than the jaw, sporadic Burkitt lymphoma typically starts in the abdomen, most often near the junction of the small and large intestines. Patients tend to show up with abdominal pain, bloating, nausea, vomiting, or gastrointestinal bleeding. Adults are more likely to also experience fevers, unexplained weight loss, and drenching night sweats.
Immunodeficiency-Related Burkitt Lymphoma
This variant is tied primarily to HIV infection and, less commonly, to immunosuppressive drugs taken after organ transplantation. Its incidence in the United States is 22 per 100,000 person-years among people with HIV. Among HIV-positive patients who develop Burkitt lymphoma, about 24% already have cancer cells in their central nervous system at the time of diagnosis, a rate notably higher than in other subtypes.
Symptoms and Speed of Growth
Because of that 66-hour doubling time (with a range of 39 to 117 hours), symptoms can escalate from barely noticeable to alarming within one to two weeks. A lump in the jaw, neck, or abdomen may seem to appear almost overnight. In children with the endemic form, parents often notice swelling in the jaw or around one eye that grows visibly day to day.
In sporadic cases, the early signs are easy to mistake for a stomach bug or intestinal problem. Persistent abdominal pain that worsens over days, a feeling of fullness, or unexplained nausea should raise concern, especially if accompanied by fever or rapid weight loss. Some patients develop bowel obstruction as the tumor mass presses on the intestines.
The tumor can also spread to the bone marrow, ovaries, kidneys, or breast. When it reaches the central nervous system, headaches, changes in vision, or facial numbness may occur.
How It’s Diagnosed
Diagnosis requires a tissue biopsy. Under the microscope, the tumor cells have a distinctive “starry sky” pattern created by scattered immune cells called macrophages clearing debris among densely packed cancer cells. Pathologists then run a panel of protein markers on the tissue. Burkitt cells are positive for CD10 and BCL6 but negative for BCL2, a combination that helps separate them from other aggressive B-cell lymphomas like diffuse large B-cell lymphoma (DLBCL).
The proliferation index, measured by a marker called MIB-1, approaches 100% in true Burkitt lymphoma. If it falls significantly below that, the diagnosis may shift toward a different lymphoma subtype. Genetic testing to confirm the MYC translocation provides the final piece of the puzzle. The fifth edition of the WHO classification of blood and lymphoid cancers continues to define Burkitt lymphoma around this combination of cell appearance, protein markers, and genetic changes.
Treatment Approach
Paradoxically, Burkitt lymphoma’s extreme growth rate makes it highly sensitive to chemotherapy. Cells that divide rapidly are more vulnerable to drugs designed to disrupt cell division. Treatment is intensive, typically involving short, high-dose chemotherapy cycles rather than the longer, lower-dose schedules used for slower-growing cancers.
The most widely used regimens alternate between two different drug combinations in rapid succession, with each cycle lasting a few weeks. These protocols also include a targeted antibody called rituximab, which binds to a protein (CD20) on the surface of the lymphoma cells and helps the immune system destroy them. Adding rituximab to chemotherapy has improved both event-free survival and overall survival in clinical trials without significantly increasing side effects.
One critical part of treatment is protecting the central nervous system. Burkitt lymphoma has a high tendency to spread to the brain and spinal fluid. About 19% of patients already have central nervous system involvement at diagnosis. Because relapse in the brain or spinal cord carries an extremely poor prognosis, most treatment protocols include preventive therapy delivered directly into the spinal fluid or through high-dose intravenous drugs capable of crossing the blood-brain barrier. Patients with limited, early-stage disease may be able to skip this step, but anyone with advanced disease receives it as standard care.
Treatment is demanding. Hospital stays, multiple cycles over several months, and significant side effects including low blood counts and infection risk are common. But the intensity is deliberate: these cancers need to be hit hard and fast because any surviving cells can regrow within days.
Survival and Prognosis
Age is the single biggest factor in outcomes. An analysis of U.S. cases diagnosed between 2000 and 2013 found five-year relative survival rates of 90.4% in children, 47.8% in adults, and 28.9% in patients over 60. The gap reflects both biology and treatment tolerance. Children generally handle intensive chemotherapy better, and their tumors tend to be diagnosed at an earlier stage.
Among adults treated with rituximab-enhanced regimens, prospective studies have reported two-year overall survival around 84%, with low-risk patients reaching 100%. High-risk patients, including those with bone marrow or central nervous system involvement, still achieve two-year survival rates near 81% with aggressive treatment. Early diagnosis and prompt initiation of therapy remain the strongest predictors of a good outcome, especially given how quickly the tumor can progress if left untreated.